VCYT vs CDNA

For growth investors, Veracyte, Inc.

(VCYT) is the stronger pick with 16. 0% revenue growth year-over-year, versus 13. 8% for CareDx, Inc (CDNA). Veracyte, Inc. (VCYT) offers the better valuation at 50. 2x trailing P/E (24. 8x forward), making it the more compelling value choice. Analysts rate Veracyte, Inc. (VCYT) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, CareDx, Inc is actually cheaper at 22.

3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Veracyte, Inc.

(VCYT) delivered a total return of -6. 0%, compared to -71. 2% for CareDx, Inc (CDNA). Over 10 years, the gap is even starker: VCYT returned +669. 9% versus CDNA's +380. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CareDx, Inc (CDNA) is the lower-risk stock at 1.

39β versus Veracyte, Inc. 's 1. 52β — meaning VCYT is approximately 9% more volatile than CDNA relative to the S&P 500. On balance sheet safety, Veracyte, Inc. (VCYT) carries a lower debt/equity ratio of 3% versus 6% for CareDx, Inc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Veracyte, Inc.

(VCYT) is pulling ahead at 16. 0% versus 13. 8% for CareDx, Inc (CDNA). On earnings-per-share growth, the picture is similar: Veracyte, Inc. grew EPS 164. 5% year-over-year, compared to -143. 0% for CareDx, Inc. Over a 3-year CAGR, VCYT leads at 20. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Veracyte, Inc.

(VCYT) is the more profitable company, earning 12. 8% net margin versus -5. 6% for CareDx, Inc — meaning it keeps 12. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VCYT leads at 14. 3% versus -5. 5% for CDNA. At the gross margin level — before operating expenses — VCYT leads at 69. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CareDx, Inc (CDNA) trades at 22.

3x forward P/E versus 24. 8x for Veracyte, Inc. — 2. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CDNA: 14. 6% to $24. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Veracyte, Inc.

(VCYT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+669. 9% 10Y return). Both have compounded well over 10 years (VCYT: +669. 9%, CDNA: +380. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VCYT is a small-cap high-growth stock; CDNA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.